Literature DB >> 23953849

Awareness of hepatitis B virus reactivation among physicians authorized to prescribe chemotherapy.

Kamuran Turker1, Berna Oksuzoglu, Elcin Balci, Ummugul Uyeturk, Medine Hascuhadar.   

Abstract

Entities:  

Keywords:  Chemotherapy; Clinical practice; HBV reactivation; Physician awareness; Prophylaxis

Mesh：

Substances：

Year:  2013        PMID： 23953849     DOI： 10.1016/j.ejim.2013.07.008

Source DB:  PubMed          Journal:  Eur J Intern Med        ISSN： 0953-6205            Impact factor:   4.487


× No keyword cloud information.
  4 in total

1.  Gastroenterologists Have Suboptimal Hepatitis B Virus Screening Rates in Patients Receiving Immunosuppressive Therapy.

Authors:  Sonali Paul; Asim Shuja; Idy Tam; Eun Min Kim; Sandra Kang; Leonid Kapulsky; Kathleen Viveiros; Hannah Lee
Journal:  Dig Dis Sci       Date:  2016-03-18       Impact factor: 3.199

2.  Using health-system-wide data to understand hepatitis B virus prophylaxis and reactivation outcomes in patients receiving rituximab.

Authors:  Gabriela Schmajuk; Chris Tonner; Laura Trupin; Jing Li; Urmimala Sarkar; Dana Ludwig; Stephen Shiboski; Marina Sirota; R Adams Dudley; Sara Murray; Jinoos Yazdany
Journal:  Medicine (Baltimore)       Date:  2017-03       Impact factor: 1.889

3.  Rituximab plus chemotherapy as first-line treatment in Chinese patients with diffuse large B-cell lymphoma in routine practice: a prospective, multicentre, non-interventional study.

Authors:  Jianqiu Wu; Yongping Song; Liping Su; Li Xu; Tingchao Chen; Zhiyun Zhao; Mingzhi Zhang; Wei Li; Yu Hu; Xiaohong Zhang; Yuhuan Gao; Zuoxing Niu; Ru Feng; Wei Wang; Jiewen Peng; Xiaolin Li; Xuenong Ouyang; Changping Wu; Weijing Zhang; Yun Zeng; Zhen Xiao; Yingmin Liang; Yongzhi Zhuang; Jishi Wang; Zimin Sun; Hai Bai; Tongjian Cui; Jifeng Feng
Journal:  BMC Cancer       Date:  2016-07-26       Impact factor: 4.430

4.  Three-year Follow-up on the Safety and Effectiveness of Rituximab Plus Chemotherapy as First-Line Treatment of Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in Real-World Clinical Settings in China: A Prospective, Multicenter, Noninterventional Study.

Authors:  Jian-Qiu Wu; Yong-Ping Song; Li-Ping Su; Ming-Zhi Zhang; Wei Li; Yu Hu; Xiao-Hong Zhang; Yu-Huan Gao; Zuo-Xing Niu; Ru Feng; Wei Wang; Jie-Wen Peng; Xiao-Lin Li; Xue-Nong Ouyang; Chang-Ping Wu; Wei-Jing Zhang; Yun Zeng; Zhen Xiao; Ying-Min Liang; Yong-Zhi Zhuang; Ji-Shi Wang; Zi-Min Sun; Hai Bai; Tong-Jian Cui; Ji-Feng Feng
Journal:  Chin Med J (Engl)       Date:  2018-08-05       Impact factor: 2.628
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.